Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
